Showing 2851-2860 of 3597 results for "".
- DermTech Files for Voluntary Chapter 11 Protectionhttps://practicaldermatology.com/news/dermtech-files-voluntary-chapter-11-protection/2467087/DermTech announced it has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company’s strategic alternatives review process. DermTech, which is a provider of noninvasive skin genomics technol
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Suntegrity Recalls Multiple Lots of Sunscreen Foundationhttps://practicaldermatology.com/news/suntegrity-recalls-multiple-lots-sunscreen-foundation/2467041/Suntegrity Skincare has announced that it is recalling nine lots of Suntegrity Impeccable Skin Sunscreen Foundation (Multiple Shades) due to the discovery of a higher-than-acceptable microbiological mold count (Aspergillus sydowii), according to an FDA alert. According to the man
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Rinvoq Now Available for Pediatric Patients with Psoriatic Arthritis and Polyarticular Juvenile Idiopathic Arthritishttps://practicaldermatology.com/news/rinvoq-now-available-pediatric-patients-psoriatic-arthritis-and-polyarticular-juvenile-idiopathic-arthritis/2466955/AbbVie announced that its blockbuster drug Rinvoq (upadacitinib) is now indicated in the US for the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). The medication is indicated for those who had
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- Innovent Plans to Submit NDA in China for Plaque Psoriasis Treatment Picankibart Following Phase 3 Datahttps://practicaldermatology.com/news/innovent-plans-submit-nda-china-plaque-psoriasis-treatment-picankibart-following-phase-3-data/2463195/Innovent Biologics announced that picankibart (IBI112) has met all the primary endpoints and key secondary endpoints in the phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis. CLEAR-1 is global the first phase 3 registration study in IL-23p